Business Context and Reporting Period
Protalix Biotherapeutics, Inc. filed this Form 8-K on February 16, 2017, to disclose a Regulation FD event. The report details the Company's participation in the Lysosomal Disease Network 13th Annual WORLD Symposium held in San Diego, CA, from February 13 through 17, 2017.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial data disclosures and does not contain financial statements.
Material Changes
The primary material event is the presentation of positive data from the Company's phase I/II dose-ranging clinical trial of PRX-102 (pegunigalsidase alfa) for the treatment of Fabry disease. Key presentations included:
- Dr. Yoseph Shaaltiel (EVP, R&D): Characterization of the chemically modified plant cell culture-expressed human alpha-galactosidase-A enzyme.
- Dr. Derralynn Hughes (Principal Investigator): One-year follow-up data on safety and efficacy of IV administration in Fabry disease patients.
- Prof. David Warnock: Immunogenicity and pharmacokinetic (PK) results from the phase 1-2 study.
Outlook, Risks, and Management Commentary
Management highlighted the positive nature of the data presented regarding PRX-102. The Company indicated that the full presentations and posters are available on its website under the Presentations tab. No specific forward-looking guidance, risk factors, or contingencies were detailed in this specific filing beyond the standard disclosure of clinical trial progress.
Investor Verification Checklist
- Verify the full text of the oral and poster presentations on the Company's website.
- Review the specific safety and efficacy metrics from the one-year follow-up data presented by Dr. Hughes.
- Confirm the immunogenicity and PK results presented by Prof. Warnock.
- Monitor subsequent regulatory filings for updates on the phase I/II trial status.